Berlin, Germany

Oliver Seitz

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Oliver Seitz - A Visionary Inventor in Cell Targeting Technology

Introduction

Oliver Seitz is an innovative inventor based in Berlin, Germany. With a total of three patents to his name, he is making significant contributions to the field of molecular targeting and peptide purification.

Latest Patents

One of Oliver's notable inventions is related to Langerin+ cell targeting. This invention focuses on utilizing a vehicle for the specific molecular targeting of Langerin+ cells. The vehicle comprises at least one carrier and at least one saccharide moiety-based conjugate, enabling targeted cargo delivery into a Langerin+ cell. The invention also includes pharmaceutical compositions and uses involving this novel vehicle.

Another significant patent pertains to the method for purifying peptides produced by solid phase peptide synthesis (SPPS). This invention outlines corresponding linker molecules that facilitate the purification of these peptides, streamlining processes in biochemistry and pharmaceutical development.

Career Highlights

Oliver has made substantial strides in his career, working with esteemed organizations such as Belyntic GmbH and the Max Planck Society for the Advancement of Science. His commitment to advancing cellular and peptide technologies is evident in his research and patents.

Collaborations

Oliver has collaborated with fellow researchers Robert Zitterbart and Christoph Rademacher, enhancing the breadth of knowledge and expertise in his innovative projects. Their combined efforts continue to drive forward the field of molecular targeting and peptide synthesis.

Conclusion

In conclusion, Oliver Seitz stands out as a prominent figure in the realm of innovative inventions that significantly contribute to biomedical research. His work in targeting Langerin+ cells and the purification of peptides reflects his dedication to advancing scientific understanding and applications, making a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…